A conversation with biotech leader, Sujal Shah, former CEO of CymaBay Therapeutics about his company's story arc, leadership, resilience, and building a biotech company in the face of adversity.

Questions?: drugdealinpod@gmail.com

Follow us on X: https://x.com/DrugDealinPod

Connect with Shivu: https://linktr.ee/shivusharma

Check out Big Pharma Sharma: https://bigpharmasharma.substack.com/

Connect with Kenny: https://www.linkedin.com/in/kennylalwani/

Disclaimer: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.

00:00 Introduction to Biotech Leadership

03:00 Sujal Shah's Journey in Biotech

05:46 Leadership Philosophy and Team Dynamics

09:13 Navigating Challenges at CymaBay

11:48 The Development of seladelpar

15:07 Strategic Decisions in Drug Development

17:58 Clinical Trials and Regulatory Interactions

20:50 The NASH Study and Its Implications

47:10 Navigating Drug Development Challenges

49:07 The Patient-Centric Approach in Drug Development

51:56 Facing Clinical Setbacks and Organizational Resilience

53:36 Unexpected Findings and Immediate Reactions

01:00:27 The Emotional Toll of Drug Development

01:05:08 Rebuilding Purpose and Finding Answers

01:19:52 Patient Advocacy and Support During Crisis

01:23:30 Uncovering the Truth: The Role of Independent Panels 01:33:59 Independent Review and Safety Assurance

01:36:50 Leadership Challenges and Stakeholder Management 01:40:12 Resilience in Adversity

01:43:51 Turning Point: Stock Recovery and Investor Relations 01:47:07 Skepticism and Ongoing Challenges

01:55:00 Data Presentation and Competitive Landscape

02:01:11 Building a Robust Evidence Package

02:04:53 Reflections on Leadership and Future Aspirations